Healthcare [ 11/13 ] | Biotechnology [ 91/159 ]
NASDAQ | Common Stock
| Reported Date | EPSChange YoY | EstimateSurprise |
|---|---|---|
| Mar 18, 24 | -0.23 Increased by +30.3% | -0.34 Increased by +32.35% |
| Nov 9, 23 | -0.33 Increased by +17.5% | -0.32 Decreased by -3.13% |
| Aug 10, 23 | -0.31 Increased by +29.55% | -0.33 Increased by +6.06% |
| May 11, 23 | -0.29 Increased by +23.68% | -0.32 Increased by +9.38% |
| Mar 30, 23 | -0.33 Increased by +5.71% | -0.36 Increased by +8.33% |
| Nov 10, 22 | -0.4 Decreased by -2.56% | -0.34 Decreased by -17.65% |
| Aug 11, 22 | -0.44 Increased by +2.22% | -0.34 Decreased by -29.41% |
| May 12, 22 | -0.38 Decreased by -31.03% | -0.31 Decreased by -22.58% |
| Fiscal ending date | RevenueChange YoY | IncomeChange YoY | ProfitChange YoY |
|---|---|---|---|
| Dec 31, 23 | 0 Decreased by N/A% | -23.71 M Increased by +27.56% | Decreased by N/A% Decreased by N/A% |
| Sep 30, 23 | 0 Decreased by N/A% | -32.88 M Increased by +18.06% | Decreased by N/A% Decreased by N/A% |
| Jun 30, 23 | 0 Decreased by N/A% | -31.51 M Increased by +28% | Decreased by N/A% Decreased by N/A% |
| Mar 31, 23 | 3.6 M Increased by +N/A% | -29.06 M Increased by +23.35% | Decreased by -807.11% Decreased by N/A% |
| Dec 31, 22 | 0 Increased by +100% | -32.74 M Increased by +4.86% | Decreased by N/A% Decreased by N/A% |
| Sep 30, 22 | 0 Decreased by N/A% | -40.13 M Decreased by -4.61% | Decreased by N/A% Decreased by N/A% |
| Jun 30, 22 | 0 Decreased by N/A% | -43.76 M Increased by +1.29% | Decreased by N/A% Decreased by N/A% |
| Mar 31, 22 | 0 Decreased by -100% | -37.91 M Decreased by -33.31% | Decreased by N/A% Decreased by N/A% |
Adverum Biotechnologies, Inc., a clinical-stage company, develops gene therapy product candidates to treat ocular diseases. Its lead product candidate is ixoberogene soroparvovec (ADVM-022), a single intravitreal injection gene therapy candidate used for the treatment of patients with wet age-related macular degeneration and diabetic macular edema which is in phase 2 clinical trials. The company is developing ADVM-062 (AAV.7m8-L-opsin), a novel gene therapy product candidate for the treatment of blue cone monochromacy via a single IVT injection. Adverum Biotechnologies, Inc. has license and collaboration agreements with University of California; GenSight Biologics; Lexeo Therapeutics; and Virovek, Inc. The company was formerly known as Avalanche Biotechnologies, Inc. and changed its name to Adverum Biotechnologies, Inc. in May 2016. Adverum Biotechnologies, Inc. was incorporated in 2006 and is headquartered in Redwood City, California.